Drug treatment may benefit only select group of patients with glioblastoma
the ONA take:
Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas. They found that the drug does inhibit proteins that promote tumor growth; however, it also inhibits proteins that protect against cancer, a finding that negates any benefit of using the drug for patients with glioblastoma.
Findings from the researchers at Mayo Clinic, who conducted one of the clinical trials, suggest that pretesting glioblastoma biopsies may help identify those patients who will benefit from treatment with dasatinib. The drug is a general Src-family kinase (SFK) inhibitor.
The researchers teased apart the effect on individual Src family members (Src, Fyn, Yes, and Lyn). They found that dasatinib inhibited Src, Fyn, and Yes, which reduced growth and migration. It also inhibited Lyn, which protects against cancer growth.
The researchers also found that tumors express all members of the Src family differently, and expression of Yes and Lyn differed among tumors.
Although further testing is needed, the findings suggest that some patients may derive benefit from treatment with dasatinib, in particular those whose tumors express Yes, but not Lyn.
Clinicians testing dasatinib, approved for several blood cancers, were hoping to find that it would slow the growth of glioblastomas.
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- Directly Informing Patients of Breast Cancer Risk, Options Improves Follow-Up Screening
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- CTCs Promising as Biomarker to Identify Lung Cancer Recurrence
- Hypofractionated RT, Conventional RT Comparable in Intermediate-Risk Prostate Cancer
- Social Functioning Scores for Young Cancer Survivors Remain Lower Than Their Peers
- Mortality Rates Highest Among Youngest Oncology Patients, Particularly Minorities
- Survey Reveals Research Priorities for Cancer Patients, Oncology Nurses
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|